By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase … Read more
People with HIV are living longer lives. That’s good news. However, it also means they’re more likely to live long enough to develop age-related diseases, such as dementia. Dementia is a loss of mental skills that affects your daily life. It can cause problems with memory, problem-solving, and learning. The risk of dementia among older … Read more
By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFU) in the second quarter … Read more
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 3rd quarter 2024 financial results on November 14th which were largely in line with expectations. Research and development expenses for the quarter ending September 30, 2024 were $2.2 million compared to $2.7 million in the prior year period. The R&D decrease … Read more
By Lisa Thompson OTC:CLPMF READ THE FULL CLPMF RESEARCH REPORT Revenue is ramping even faster than we expected, as shown by the Q3 earnings report. Revenue for Q3 2024 was $521,000 compared to $149,000 in Q3 of 2023, representing 250% growth. In the quarter, the number of new deposit users grew by 101%, and revenue … Read more
